Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/JPRN-UMIN000046035
JPRN-UMIN000046035Completed未知

Analysis of corneal endothelial dysfunction - Analysis of corneal endothelial dysfunction

Kawasaki Medical School0 sites24 target enrollmentStarted: November 11, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Enrollment
24
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The mean logMAR visual acuity was improved at 3, 6, 12, and 18 months after ripasudil administration. LogMAR changes 18 months after administration were 0.181 0.170 in the ripasudil group and were significantly superior (P = 9.5 10-4) to those in the control group (-0.057 0.106).

Study Design

Study Type
Observational

Eligibility Criteria

Ages
20years-old to 110years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Active ocular surface disease.

Investigators

Similar Trials

Completed
Not Applicable
Efficacy and safety of ripasudil hydrochloride in glaucoma patients being treated by prostaglandin analogues, but their intraocular pressures are 15mmHg or under.glaucoma
JPRN-UMIN000030742Yotsuya Shirato Ophthalmology Clinic30
Completed
Not Applicable
Evaluation for topical use of ripasudil as ophthalmic solution.Glaucoma
JPRN-UMIN000046037Kawasaki Medical School26
Completed
Not Applicable
Evaluation of general condition before and after vitreous anti-VEGF drug administration for diabetic macular edema
JPRN-UMIN000044287Fukui University112
Completed
Phase 4
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein OcclusionBranch Retinal Vein Occlusion
NCT02478515Nagoya City University27
Recruiting
Not Applicable
Effect of ripasudil on corneal endothelial damage after glaucoma tube shunt surgeryglaucoma
JPRN-UMIN000042504Hiroshima University Hospital100